<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718286</url>
  </required_header>
  <id_info>
    <org_study_id>EPIC.STEMI.2018</org_study_id>
    <nct_id>NCT03718286</nct_id>
  </id_info>
  <brief_title>Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI</brief_title>
  <acronym>EPIC STEMI</acronym>
  <official_title>Effects of Acute, Rapid Lowering of Low Density Lipoprotein Cholesterol With Alirocumab in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo controlled parallel group clinical trial evaluating the
      effects of acute treatment with a PCSK9 inhibitor (alirocumab) versus placebo on low-density
      lipoprotein (LDL) in 100 high-risk patients presenting with STEMI and referred for primary
      PCI.

      The objective is to determine the effect of acute, rapid lowering of LDL cholesterol with
      alirocumab added to high dose statin therapy in patients with STEMI undergoing primary PCI.
      The hypothesis is that, in patients with STEMI undergoing primary PCI, rapid lowering of LDL
      cholesterol with a PCSK9 Inhibitor (alirocumab) initiated in the acute setting pre-PCI, will
      favourably affect LDL cholesterol concentrations compared with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blind, sham-controlled parallel group clinical trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in direct LDL cholesterol</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apo B</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipidemias</condition>
  <condition>Dyslipidemias</condition>
  <condition>Physiological Effects of Drugs</condition>
  <arm_group>
    <arm_group_label>Alirocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab</intervention_name>
    <description>150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.</description>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Control</intervention_name>
    <description>Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.</description>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting with STEMI defined as both of the following: a) Symptoms of
             myocardial ischemia lasting for ≥ 30 minutes, and b) Definite ECG changes indicating
             STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in
             two contiguous precordial leads.

          -  Referred for primary PCI for presenting symptoms.

          -  Randomized within 12 hours of symptom onset and prior to diagnostic angiography.

        Exclusion Criteria:

          -  Age ≤18 years.

          -  Pregnancy or breastfeeding.

          -  Current or planned treatment with a PCSK9 inhibitor.

          -  Allergy or contra-indication to a PCSK9 inhibitor.

          -  Killip class ≥2.

          -  Known Creatinine clearance &lt;30mL/min.

          -  Suspected takotsubo / stress-induced cardiomyopathy or acute pericarditis.

          -  Any other medical, geographic, or social factor making study participation impractical
             or precluding follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shamir Mehta, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute; McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandi Meeks, MSc</last_name>
    <phone>9055212100</phone>
    <email>epicstemi@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helen Nguyen</last_name>
    <phone>9055212100</phone>
    <email>epicstemi@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton Health Sciences, General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator, MD</last_name>
    </contact>
    <contact_backup>
      <email>epicstemi@phri.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

